Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2022

Conditions
Cutaneous T Cell Lymphoma
Interventions
DRUG

Dimethyl fumarate

dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur

Trial Locations (1)

68167

University Medical Center, Mannheim

All Listed Sponsors
collaborator

Klinikum Minden

UNKNOWN

collaborator

Klinikum Krefeld

UNKNOWN

collaborator

Wuerzburg University Hospital

OTHER

collaborator

KKS Netzwerk

NETWORK

collaborator

Klinikum Ludwigshafen

OTHER

collaborator

Universitätsklinikum Kiel

UNKNOWN

lead

Universitätsmedizin Mannheim

OTHER

NCT02546440 - Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) | Biotech Hunter | Biotech Hunter